Open Access

A novel method to detect the Mexican founder mutation BRCA1 ex9‑12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes

  • Authors:
    • Denisse Aideé Martínez‑Treviño
    • Rafael Baltazar Reyes León‑Cachón
    • Cynthia Villarreal‑Garza
    • Dione Aguilar Y Méndez
    • Elisa Aguilar‑Martínez
    • Hugo Alberto Barrera‑Saldaña
  • View Affiliations

  • Published online on: June 6, 2018     https://doi.org/10.3892/mmr.2018.9141
  • Pages: 1531-1537
  • Copyright: © Martínez‑Treviño et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In 2015, according to the National Institute of Statistics and Geography (INEGI), malignant breast tumors were the first cause of cancer fatality in women (6,273 fatalities) in Mexico, whereas 2,793 fatalities in women were due to ovarian cancer. A total of 5‑10% of breast cancer and 10‑15% of ovarian cancer cases are caused by a hereditary breast‑ovarian cancer syndrome, with mutations predominantly identified in the BRCA1 and BRCA2 genes. Recently, the Mexican founder mutation BRCA1 ex9‑12del was identified (deletion of exons 9‑12 with recombination between introns 8‑12). This is the most frequently reported mutation in hereditary breast/ovarian cancer in Mexico. Current detection methods include end‑point polymerase chain reaction (PCR) and Multiplex Ligation‑dependent Probe Amplification (MLPA). In the present study a cheap, sensitive and fast detection method was developed based on quantitative PCR and two TaqMan® probes, one to detect the deletion (recombination region between introns 8 and 12), and the other one a region from exon 11. With this assay, 90 samples were able to be analyzed in 2 h using 2.5 ng of DNA/reaction at a cost of ~2‑3 USD. This method is capable of detecting positive samples for DNA deletion and excluding negative ones. Therefore, the method proposed may be a useful high‑throughput diagnostic option that could be useful in future association or prevalence studies that use large populations.
View Figures
View References

Related Articles

Journal Cover

August 2018
Volume 18 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Martínez‑Treviño, D.A., León‑Cachón, R.B., Villarreal‑Garza, C., Aguilar Y Méndez, D., Aguilar‑Martínez, E., & Barrera‑Saldaña, H.A. (2018). A novel method to detect the Mexican founder mutation BRCA1 ex9‑12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes. Molecular Medicine Reports, 18, 1531-1537. https://doi.org/10.3892/mmr.2018.9141
MLA
Martínez‑Treviño, D. A., León‑Cachón, R. B., Villarreal‑Garza, C., Aguilar Y Méndez, D., Aguilar‑Martínez, E., Barrera‑Saldaña, H. A."A novel method to detect the Mexican founder mutation BRCA1 ex9‑12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes". Molecular Medicine Reports 18.2 (2018): 1531-1537.
Chicago
Martínez‑Treviño, D. A., León‑Cachón, R. B., Villarreal‑Garza, C., Aguilar Y Méndez, D., Aguilar‑Martínez, E., Barrera‑Saldaña, H. A."A novel method to detect the Mexican founder mutation BRCA1 ex9‑12del associated with breast and ovarian cancer using quantitative polymerase chain reaction and TaqMan® probes". Molecular Medicine Reports 18, no. 2 (2018): 1531-1537. https://doi.org/10.3892/mmr.2018.9141